Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02175082
Other study ID # STU00093757
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 2014
Est. completion date June 2019

Study information

Verified date October 2020
Source Shirley Ryan AbilityLab
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness of a forced exercise aerobic exercise program, utilizing a cycling activity, on specific gait parameters and balance in individuals with Parkinson's Disease (PD). Design: pilot, feasibility, randomized control, evaluator blinded. Subjects: Twenty four patients with idiopathic PD Hoehn and Yahr (H&Y) stage II or III. Intervention: Participants randomly assigned to one of two exercise groups, forced exercise or self selected exercise, on cycling machine three times a week for 8 weeks. Both groups to exercise at same aerobic intensity level to keep heart rate at 60-80% heart rate max. Outcomes: Gait parameters of step length, width, and variability as measured by the GAITRite; 6 Minute Walk Test; mini-BESTest (balance testing); exercise tolerance via Patient Reported Outcomes Measurement Information System (PROMIS) scale.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Idiopathic Parkinson's Disease - Hoehn and Yahr Stages II - III. - Ages 30-80 years - Medical Clearance - Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: - MOCA: (Montreal Cognition Scale) : rating of less than 24, indicative of cognitive dysfunction - Changes in Parkinson's medications within the two weeks prior to starting the study - Anticipated change in Parkinson Disease medications during the course of the study - Uncontrolled orthostasis - Symptomatic coronary artery disease - Fracture of lower limb within 6 months prior to study onset or significant lower limb orthopedic diagnosis that would limit cycling - Other significant neurologic diagnoses including multiple sclerosis or vestibular disease - Acute illness - Physical therapy within the month prior to study entry - Subjects already participating in a forced exercise or high intensity exercise program - Any medical condition that the physician investigator determined would compromise safety.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cycling at Forced rate

Cycling at self-selected rate


Locations

Country Name City State
United States Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago) Chicago Illinois

Sponsors (3)

Lead Sponsor Collaborator
Shirley Ryan AbilityLab Northwestern Memorial Hospital, Paul Ruby Foundation for Parkinson's Research

Country where clinical trial is conducted

United States, 

References & Publications (1)

Sung P, Rafferty M, Doyle L, Kliver E, Bines K, Traines J, Scarpa A, Marciniak C, Solanki S, Todd A. Technology-based Forced Paced Cycling in Parkinson's disease: Is it Feasible and Effective?Archives of PM&R October 2019Volume 100, Issue 10, Page e126

Outcome

Type Measure Description Time frame Safety issue
Other Steps per day Subjects steps per day will be measured with a Garmin wrist step counter Over 8 week trial and for 2 months post intervention
Primary 6-minute walk test Distance walked in 6 minutes 8 weeks
Secondary Stride length Length of stride in meters as measured by the GAITrite 8 weeks
Secondary Step Width Width of step in meters as measured by the GAITrite 8 weeks
Secondary Step variability Standard deviation of step as measure in meters by the Gaitrite system 8 weeks
Secondary 10 meter walk test Time in seconds for the subject to walk 10 meters 8 weeks
Secondary miniBESTest (Balance Evaluation Systems Test) Subject is scored as the 14 activities on this scale are performed, and a summary score is derived. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02874274 - Vaccination Uptake (VAX) in PD N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A

External Links